We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+48.92%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$7.15B
AUM Growth
+$1.69B
Cap. Flow
+$592M
Cap. Flow %
8.27%
Top 10 Hldgs %
50.83%
Holding
92
New
22
Increased
4
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
NVAX icon
Novavax
NVAX
+$275M
2
AVIR icon
Atea Pharmaceuticals
AVIR
+$173M
3
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$144M
4
OLMA icon
Olema Pharmaceuticals
OLMA
+$101M
5
RCKT icon
Rocket Pharmaceuticals
RCKT
+$77.9M

Top Sells

Rank Stock Value
1
MCRB icon
Seres Therapeutics
MCRB
+$134M
2
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$109M
3
PCVX icon
Vaxcyte
PCVX
+$58.5M
4
VXRT
Vaxart
VXRT
+$51.3M
5
ADAP
Adaptimmune Therapeutics
ADAP
+$48M

Sector Composition

Rank Sector Weight
1 Healthcare 99.54%
2 Financials 0.3%
3 Miscellaneous 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNA
51
DELISTED
Verona Pharma
VRNA
$31.8M 0.44%
5,100,000
– –
PAND
52
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
$26.3M 0.37%
1,770,023
– –
ALEC icon
53
Alector
ALEC
$228M
$24.5M 0.34%
1,616,879
-2,001,869
-55% -$24.9M
CNCE
54
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$23M 0.32%
1,823,520
-34,954
-2% -$398K
SNDX icon
55
Syndax Pharmaceuticals
SNDX
$1.62B
$22.8M 0.32%
1,023,067
– –
STSA
56
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$21.6M 0.3%
4,681,858
– –
ORIC icon
57
Oric Pharmaceuticals
ORIC
$1.28B
$19.8M 0.28%
+584,000
New +$16.8M
SCPH
58
DELISTED
scPharmaceuticals
SCPH
$18.6M 0.26%
3,518,998
– –
MRNS
59
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$15.9M 0.22%
+1,300,000
New +$18.1M
VXRT
60
DELISTED
Vaxart
VXRT
$15.7M 0.22%
2,742,271
-8,068,666
-75% -$51.3M
MIST icon
61
Milestone Pharmaceuticals
MIST
$115M
$15.6M 0.22%
2,327,714
-91,084
-4% -$610K
OCUL icon
62
Ocular Therapeutix
OCUL
$2.24B
$15.5M 0.22%
750,000
-1,977,272
-72% -$29.4M
TNGX icon
63
Tango Therapeutics
TNGX
$4.03B
$14.3M 0.2%
1,250,000
– –
RPTX
64
DELISTED
Repare Therapeutics
RPTX
$14M 0.2%
409,000
– –
BLSA
65
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$13.9M 0.19%
+1,250,000
New +$13.4M
ADAP
66
DELISTED
Adaptimmune Therapeutics
ADAP
$13.5M 0.19%
2,499,025
-8,830,556
-78% -$48M
COGT icon
67
Cogent Biosciences
COGT
$5.68B
$11.5M 0.16%
+1,025,641
New +$11.3M
NAUT icon
68
Nautilus Biotechnolgy
NAUT
$113M
$10.8M 0.15%
1,000,000
– –
FLACU
69
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$10.4M 0.15%
+1,000,000
New +$10.4M
TXMD icon
70
TherapeuticsMD
TXMD
$25M
$9.45M 0.13%
+156,250
New +$10.7M
LYRA
71
DELISTED
LYRA THERAPEUTICS INC
LYRA
$9.3M 0.13%
16,317
– –
PASG icon
72
Passage Bio
PASG
$15.3M
$8.25M 0.12%
16,132
– –
OBIO icon
73
Orchestra BioMed
OBIO
$363M
$8.01M 0.11%
625,000
– –
CRNX
74
DELISTED
Crinetics Pharmaceuticals
CRNX
$7.96M 0.11%
564,102
-1,764,596
-76% -$24.6M
MLTX icon
75
MoonLake Immunotherapeutics
MLTX
$1.04B
$7.96M 0.11%
+700,000
New +$7.43M
1 2
3
4

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, RA Capital Management held 92 positions worth $7.15B, up 31% from $5.47B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

RA Capital Management deployed $592M of net new capital in Q4 2020, opening 22 new positions and adding to 4 existing holdings. Its largest new stake was Atea Pharmaceuticals: 5,368,451 shares worth $224M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Vaxcyte, an estimated $58.5M trimmed.

  • RA Capital Management's largest Q4 2020 buy was Atea Pharmaceuticals: 5,368,451 shares worth $224M.
  • RA Capital Management added most to Novavax in Q4 2020, an estimated $275M increase.
  • RA Capital Management's biggest Q4 2020 reduction was Vaxcyte, cutting an estimated $58.5M.
  • RA Capital Management fully exited Seres Therapeutics in Q4 2020, selling an estimated $134M.
  • RA Capital Management's ten largest holdings make up 51% of its $7.15B portfolio in Q4 2020.
  • RA Capital Management opened 22 new positions and closed 10 in Q4 2020.
  • RA Capital Management's portfolio value rose 31% quarter-over-quarter to $7.15B.

Based on RA Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.